Ann: Quarterly Appendix 4C and Activities Report, page-2

This, from the quarterly;
'To further explore these findings and optimise the design of Part B of the Phase I studying IPF and ILD patients, AdAlta extended the final, 20 mg/kg, healthy volunteer cohort to investigate receptor occupancy at two and three weeks following infusion. This cohort was successfully treated in January 2021 and Part A top line results are expected in early March 2021, with full results in April and Part B of the Phase I clinical studies ontrack for initiation in the June 2021 quarter'

We have already had partial results in March, with full results expected in April -- my question .
Are the full results somewhere in todays announcement ?
I read it but It is a bit too technical for my understanding .
Anyone ?
Cheers.